Business Insider

TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis

Both studies met their primary endpoint of significantly reducing annualized relapse rate (ARR)(p<0.005 in each study) with ublituximab demonstrating an ARR of <0.10 in each of the studies Relative ...
Seeking Alpha

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of ...

NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics (TGTX), Inc. , today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® ...
Morningstar

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - Morningstar

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...
Seeking Alpha

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American ...

NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics (TGTX), Inc. , today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ...